SOPHiA Genetics, Myriad team up to advance prostate cancer genomic instability score technology

PUBT · 2d ago
SOPHiA Genetics, Myriad team up to advance prostate cancer genomic instability score technology
  • SOPHiA GENETICS entered a collaboration with Myriad to advance a prostate cancer genomic instability score for AstraZeneca precision oncology trials.
  • Deal targets development of PrGIS, an HRD-related biomarker signature, for use in clinical trials and potential companion diagnostics.
  • SOPHiA GENETICS will integrate PrGIS into its Extended Homologous Recombination Solution to support decentralized testing across its global lab network.
  • Myriad’s MyChoice CDx test will generate the PrGIS score, with development underway to add prostate cancer as a new indication.
  • Myriad plans to present PrGIS research co-authored with AstraZeneca at the ESMO Congress 2026, pending embargo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via CNW (Ref. ID: 202610080900CANADANWCANADAPR_C8579) on October 08, 2026, and is solely responsible for the information contained therein.